Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. Such insurers are often building barriers to reimbursement, such as high expense restrictions and PA that restrict us